Literature DB >> 15221887

Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia.

Clare L Marchant1, F Richard Ellis, P Jane Halsall, Philip M Hopkins, Rachel L Robinson.   

Abstract

Hypokalemic periodic paralysis (HypoPP) and malignant hyperthermia (MH) are autosomal-dominant genetically heterogeneous ion channelopathies. MH has been described in patients with HypoPP, suggesting a potential link between these disorders. However, a common genetic determinant has not been described. With the aim of corroborating this association, four candidate genes were screened in two independent HypoPP patients, one of whom was also diagnosed as MH-susceptible and the other as MH-normal by the in vitro contracture test (IVCT). An A>G change at nucleotide 7025 was detected in the RYR1 gene in the HypoPP/MH-susceptible patient. Detection of the same mutation in three independent MH families suggested that 7025A>G represents a novel MH-susceptibility allele and that MH and HypoPP occurred independently in the case presented. Conclusive evidence in support of the hypothesis that MH and HypoPP are allelic was therefore not obtained.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221887     DOI: 10.1002/mus.20068

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  16 in total

Review 1.  Muscle channelopathies and critical points in functional and genetic studies.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

2.  Genetic epidemiology of malignant hyperthermia in the UK.

Authors:  D M Miller; C Daly; E M Aboelsaod; L Gardner; S J Hobson; K Riasat; S Shepherd; R L Robinson; J G Bilmen; P K Gupta; M-A Shaw; P M Hopkins
Journal:  Br J Anaesth       Date:  2018-08-17       Impact factor: 9.166

Review 3.  Channelopathies of skeletal muscle excitability.

Authors:  Stephen C Cannon
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

4.  Multi-minicore disease and atypical periodic paralysis associated with novel mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  Haiyan Zhou; Suzanne Lillis; Ryan E Loy; Farshid Ghassemi; Michael R Rose; Fiona Norwood; Kerry Mills; Safa Al-Sarraj; Russell J M Lane; Lucy Feng; Emma Matthews; Caroline A Sewry; Stephen Abbs; Stefan Buk; Michael Hanna; Susan Treves; Robert T Dirksen; Gerhard Meissner; Francesco Muntoni; Heinz Jungbluth
Journal:  Neuromuscul Disord       Date:  2010-01-18       Impact factor: 4.296

5.  Anaesthetic management of a patient with hypokalemic periodic paralysis- a case report.

Authors:  S Chitra; Grace Korula
Journal:  Indian J Anaesth       Date:  2009-04

6.  Mutations associated with hypokalemic periodic paralysis: from hotspot regions to complete analysis of CACNA1S and SCN4A genes.

Authors:  Raffaella Brugnoni; Eleonora Canioni; Massimiliano Filosto; Antonella Pini; Paola Tonin; Tommaso Rossi; Carlotta Canavese; Marica Eoli; Gabriele Siciliano; Giuseppe Lauria; Renato Mantegazza; Lorenzo Maggi
Journal:  Neurogenetics       Date:  2021-10-05       Impact factor: 2.660

7.  Malignant hyperthermia.

Authors:  Dong-Chan Kim
Journal:  Korean J Anesthesiol       Date:  2012-11-16

Review 8.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

9.  Practical aspects in the management of hypokalemic periodic paralysis.

Authors:  Jacob O Levitt
Journal:  J Transl Med       Date:  2008-04-21       Impact factor: 5.531

10.  Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.

Authors:  Werner Klingler; Sebastian Heiderich; Thierry Girard; Elvira Gravino; James Ja Heffron; Stephan Johannsen; Karin Jurkat-Rott; Henrik Rüffert; Frank Schuster; Marc Snoeck; Vincenzo Sorrentino; Vincenzo Tegazzin; Frank Lehmann-Horn
Journal:  Orphanet J Rare Dis       Date:  2014-01-16       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.